• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    A

    Atal Bihari Vajpayee Institute of Medical Sciences

    862论文总数
    8,091引用总数

    Atal Bihari Vajpayee Institute of Medical Sciences (ABVIMS), New Delhi, formerly Post Graduate Institute of Medical Education and Research (PGIMER), New Delhi is a higher Medical training and research institute at Dr. Ram Manohar Lohia Hospital, New Delhi. It is affiliated to Guru Gobind Singh Indraprastha University, New Delhi.It was established in 2009 as Post Graduation and Super-Specialty Research and training Institute.In 2019, It started MBBS course with 100 seats..

    论文量&引用量时间轴

    机构学者

    论文(863)

    年份
    起
    –
    止
    排序
    1Diagnostic Performance of Serum Creatine Kinase and Lactate in Acute Compartment Syndrome of the Extremities: A Systematic Review and Meta-analysis
    Anil Regmi, Vijay Kumar Jain, Surakshya Baral, Sachin Yashwant Kale, Sanyam Kulshrestha,Karthikeyan. P. Iyengar

    Acute compartment syndrome (ACS) is a time-critical surgical emergency requiring prompt diagnosis to prevent irreversible tissue damage. Current diagnostic methods rely on subjective clinical findings and invasive intracompartmental pressure measurement, both with significant limitations. Serum biomarkers may provide non-invasive adjuncts, particularly in patients with unreliable clinical examinations. This study aims to evaluate the diagnostic association of serum creatine kinase (CK) and lactate levels with ACS in patients with extremity trauma. A systematic literature search was performed in PubMed, Embase, and Scopus as per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guideline (PROSPERO Registration: CRD420261351683) from inception through February 2026. Studies evaluating serum CK or lactate in patients with suspected or confirmed ACS with comparison groups were included. Risk of bias was assessed using Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Threshold-based analyses pooled odds ratios (ORs) with 95

    2026Indian Journal of Orthopaedics(2026)引用:20
    引用
    AI阅读
    加入学术空间
    2SGLT2 Inhibitors and Outcomes after Surgical Aortic Valve Replacement: Attention to Detail
    Rohan Magoon, Jes Jose
    2026The Cardiothoracic Surgeon(2026)引用:5
    引用
    AI阅读
    加入学术空间
    3NeuroRAD-FM: A Distributionally Robust Foundation Model for Precision Neuro-Oncology
    Moinak Bhattacharya, Annie Singh, Angelica P. Kurtz, Fabio M. Iwamoto,Prateek Prasanna, Gagandeep Singh

    Foundation models for neuro-oncology have shown promise for non-invasive molecular characterization and prognostication, yet their clinical utility remains limited by cross-institutional distribution shift and poor performance on under-represented molecular alterations. We developed NeuroRAD-FM, combining self-supervised pretraining, Group-DRO, and a multi-backbone ensemble to learn site-invariant imaging representations. NeuroRAD-FM is pretrained on 7,414 multi-sequence brain MRI examinations aggregated from multiple institutions and evaluated on independent glioma cohorts from UCSF (n = 111), UPenn (n = 95), and an in-house cohort (n = 292). Downstream tasks included automated tumor segmentation, molecular biomarker prediction, and overall survival prediction. Compared with conventional foundation models, NeuroRAD-FM learned more site-invariant features, improved tumor segmentation across tumor types, significantly enhanced molecular marker prediction, and increased concordance indices across all institutions. These findings suggest that integrating Group-DRO with a multi-backbone foundation model enables robust, site-invariant representation learning and substantially improves molecular subtype and survival prediction across diverse neuro-oncology cohorts.

    2026引用:1
    引用
    AI阅读
    加入学术空间
    4Preoperative Fructosamine is Comparable to HbA1c As a Short-Term Glycemic Marker for Predicting Postoperative Complications in Orthopaedic Surgery: A Systematic Review and Meta-Analysis
    Anil Regmi, Abdus Sami, Surakshya Baral, Vijay Kumar Jain,Karthikeyan P Iyengar

    Objective:This study systematically evaluates the predictive value of preoperative glycaemic biomarkers, including fructosamine, compared with HbA1c and glycated albumin. Methods:The databases of PubMed, Embase, and Scopus were searched from inception to September 2025 for studies that assessed preoperative fructosamine levels and postoperative complications in orthopaedic patients. Cohort studies reporting infections, wound complications, readmissions, or reoperations were included. Data extraction and quality assessment were performed independently. A random-effects meta-analysis was used to pool risk estimates, with heterogeneity quantified using the I2 statistic. Results:Seven cohort studies (N = 5217) met the inclusion criteria. Elevated preoperative fructosamine (≈292-293 μmol/L for arthroplasty; ≈238 μmol/L for foot/ankle surgery) was consistently associated with a higher risk of postoperative infection and complications (pooled RR 7.20; 95% CI 1.49-34.91). HbA1c demonstrated a smaller, less consistent effect (pooled RR 2.36; 95% CI 1.04-5.34). Direct comparisons between high fructosamine and high HbA1c cohorts revealed no statistically significant difference, although fructosamine more accurately reflected short-term glycemic status. Conclusions:Preoperative fructosamine is a robust short-term glycaemic biomarker that frequently outperforms HbA1c in predicting postoperative infectious complications in arthroplasty and other orthopaedic surgery. Standardised cut-offs, multicenter validation, and interventional trials are needed to define its role in perioperative risk stratification.

    2026Journal of orthopaedics(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Over 600 Million People Aged 18–65 Will Have Headache Tomorrow: Global 1-Day Prevalence and Recall Bias from a Meta-Analysis of Individual Participant Data (N = 38,512) from the General Populations of 15 Countries
    Andreas Kattem Husøy,Shengyuan Yu,Ruozhuo Liu,Akbar A. Herekar, Bilal Ahmed,Arif D. Herekar,Callixte Kuate Tegueu, Anastase Dzudie Tamdja,Annick Mélanie Magnerou,Najib Kissani,Latifa Adarmouch,Thierry Adoukonou,

    Abstract Background Our recent estimate of the global 1-year prevalence of headache among those aged 18–65 years was 65%: considerably higher than previous estimates, but based solely on high-quality epidemiological data derived from a large population-based sample. Here we present complementary estimates of 1-day prevalence. Methods We performed a meta-analysis of individual participant data from cross-sectional surveys among population-representative samples (age range 18–65 years) from 15 countries and all world regions. All used the Headache-Attributed Restriction, Disability, Social Handicap and Impaired Participation (HARDSHIP) questionnaire, including the question “did you have a headache yesterday?”, from which 1-day prevalence was determined. An algorithmic process applying modified ICHD criteria yielded separate estimates for migraine, tension-type headache (TTH) and probable medication-overuse headache (pMOH: the association of headache on ≥ 15 days/month and medication overuse). We analysed associations with age, gender and country-income level, and adjusted prevalence estimates for these factors. We calculated predicted 1-day prevalence from 1-year prevalence and reported headache frequency. Results Among the 38,512 participants, females (53.4%) and participants from low- (17.1%) or lower-middle-income countries (64.6%) were overrepresented, but age distribution fairly matched that of the world. Overall, 13.7% (95% CI: 13.3–14.0) reported headache yesterday, females (17.1% [16.6–17.6]) more than males (9.7% [9.3–10.2]). Migraine was the most common headache type yesterday (6.0% [5.8–6.3]), followed by TTH (4.1% [3.9–4.3]) and pMOH (2.3% [2.2–2.5]). One-day headache prevalence was higher in low/lower-middle-income countries (13.9% [13.6–14.3]) than in high/upper-middle-income countries (12.4% [11.6–13.2]). Predicted 1-day prevalence (10.9% [10.7–11.1]) was considerably lower than observed 1-day prevalence (13.7% [13.3–14.0]), although not among those with pMOH (3.1% [3.0-3.3] versus 2.3% [2.2–2.5]). Adjusted for age, gender and country-income level, global 1-day prevalence estimates were 13.1% (12.8–13.5) for any headache, 5.7% (5.5–5.9) for migraine, 3.9% (3.7–4.1) for TTH and 2.4% (2.3–2.6) for pMOH, with 1.0% undiagnosed. Conclusion Assuming yesterday was no different from any other day, an estimated 13.1% (N = 641,900,000) of the world’s population aged 18–65 years will have headache tomorrow; almost half will be migraine. People with migraine or TTH underestimate the frequency of headache episodes. Since headache-attributed burden is usually estimated from recalled frequency over 1–12 months, this also may be underestimated.

    2026The Journal of Headache and Pain(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 863 篇论文

    合作机构(100)

    All India Institute of Medical Sciences合作论文 56
    德里大学合作论文 30
    Postgraduate Institute of Medical Education and Research合作论文 29
    Parliament of United Kingdom合作论文 23
    旁遮普大学合作论文 22
    Apollo Hospital, Indraprastha合作论文 20
    Vardhman Mahavir Medical College & Safdarjung Hospital合作论文 11
    Institute of Medical Sciences,Banaras Hindu University合作论文 11
    All India Institute of Medical Sciences, Patna合作论文 10
    塔帕尔大学合作论文 9

    机构统计